Open Collections

UBC Faculty Research and Publications

Tissue Engineered Transcatheter Pulmonary Valved Stent Implantation: Current State and Future Prospect Zhang, Xiling; Puehler, Thomas; Seiler, Jette; Gorb, Stanislav N.; Sathananthan, Janarthanan; Sellers, Stephanie; Haneya, Assad; Hansen, Jan-Hinnerk; Uebing, Anselm; Müller, Oliver J.; et al.

Abstract

Patients with the complex congenital heart disease (CHD) are usually associated with right ventricular outflow tract dysfunction and typically require multiple surgical interventions during their lives to relieve the right ventricular outflow tract abnormality. Transcatheter pulmonary valve replacement was used as a non-surgical, less invasive alternative treatment for right ventricular outflow tract dysfunction and has been rapidly developing over the past years. Despite the current favorable results of transcatheter pulmonary valve replacement, many patients eligible for pulmonary valve replacement are still not candidates for transcatheter pulmonary valve replacement. Therefore, one of the significant future challenges is to expand transcatheter pulmonary valve replacement to a broader patient population. This review describes the limitations and problems of existing techniques and focuses on decellularized tissue engineering for pulmonary valve stenting.

Item Metadata

Title
Tissue Engineered Transcatheter Pulmonary Valved Stent Implantation: Current State and Future Prospect
Creator
Zhang, Xiling; Puehler, Thomas; Seiler, Jette; Gorb, Stanislav N.; Sathananthan, Janarthanan; Sellers, Stephanie; Haneya, Assad; Hansen, Jan-Hinnerk; Uebing, Anselm; Müller, Oliver J.; Frank, Derk; Lutter, Georg
Contributor
St. Paul's Hospital (Vancouver, B.C.). Centre for Heart Valve Innovation
Publisher
Multidisciplinary Digital Publishing Institute
Date Issued
2022-01-10
Description
Patients with the complex congenital heart disease (CHD) are usually associated with right ventricular outflow tract dysfunction and typically require multiple surgical interventions during their lives to relieve the right ventricular outflow tract abnormality. Transcatheter pulmonary valve replacement was used as a non-surgical, less invasive alternative treatment for right ventricular outflow tract dysfunction and has been rapidly developing over the past years. Despite the current favorable results of transcatheter pulmonary valve replacement, many patients eligible for pulmonary valve replacement are still not candidates for transcatheter pulmonary valve replacement. Therefore, one of the significant future challenges is to expand transcatheter pulmonary valve replacement to a broader patient population. This review describes the limitations and problems of existing techniques and focuses on decellularized tissue engineering for pulmonary valve stenting.
Subject
tissue engineering; heart valve replacement; pulmonary; transcatheter; percutaneous; biodegradable; nitinol; stents; congenital heart disease; decellularization; recellularization
Genre
Article
Type
Text
Language
eng
Date Available
2022-02-18
Provider
Vancouver : University of British Columbia Library
Rights
CC BY 4.0
DOI
10.14288/1.0406618
URI
http://hdl.handle.net/2429/80856
Affiliation
Other UBC; Non UBC
Citation
International Journal of Molecular Sciences 23 (2): 723 (2022)
Publisher DOI
10.3390/ijms23020723
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher; Other
Rights URI
https://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

CC BY 4.0